View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, April 11 (HealthDay News) -- For patients who undergo endoscopic retrograde cholangiopancreatography (ERCP), a single dose of rectal indomethacin immediately after the procedure is associated with a significantly reduced incidence of pancreatitis, according to a study published in the April 12 issue of the New England Journal of Medicine.
B. Joseph Elmunzer, M.D., from the University of Michigan Medical Center in Ann Arbor, and colleagues randomly allocated 602 patients at increased risk for post-ERCP pancreatitis to receive a single dose of rectal indomethacin or placebo immediately after the procedure.
The researchers found that 82 percent of patients had clinical suspicion of sphincter of Oddi dysfunction. Post-ERCP pancreatitis developed in significantly fewer patients in the indomethacin group than the placebo group (9.2 versus 16.9 percent). In addition, moderate-to-severe pancreatitis developed in significantly fewer patients in the indomethacin group than the placebo group (4.4 versus 8.8 percent).
"Prophylactic rectal indomethacin significantly reduced the incidence and severity of post-ERCP pancreatitis in patients at elevated risk for this complication, particularly in those with a clinical suspicion of sphincter of Oddi dysfunction," the authors write.
Several authors disclosed financial relationships with pharmaceutical, medical, and biotechnology companies.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top